| 
																	
																	
																		 Nidhya Navanandan
 
																		 Concepts  (107)
																		
																	 
																		Concepts are derived automatically from a person's publications. 
																			
																					
    Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
     | Name | Number of Publications | Most Recent Publication | Publications by All Authors | Concept Score | Why? | 
|---|
 | Asthma | 14 | 2024 | 2285 | 3.710 | Why? |  | Anti-Asthmatic Agents | 5 | 2024 | 391 | 1.790 | Why? |  | Pneumonia | 7 | 2023 | 631 | 1.330 | Why? |  | Emergency Service, Hospital | 12 | 2024 | 2033 | 1.310 | Why? |  | Respiratory Tract Infections | 4 | 2024 | 395 | 1.020 | Why? |  | Respiratory Sounds | 2 | 2024 | 123 | 1.020 | Why? |  | Community-Acquired Infections | 5 | 2023 | 169 | 0.860 | Why? |  | Recurrence | 2 | 2024 | 1058 | 0.860 | Why? |  | Child | 26 | 2024 | 21896 | 0.780 | Why? |  | Virus Diseases | 2 | 2023 | 216 | 0.770 | Why? |  | Severity of Illness Index | 4 | 2024 | 2833 | 0.720 | Why? |  | Airway Resistance | 1 | 2020 | 36 | 0.680 | Why? |  | Oscillometry | 1 | 2020 | 37 | 0.670 | Why? |  | Medicaid | 1 | 2024 | 433 | 0.640 | Why? |  | Adrenal Cortex Hormones | 4 | 2024 | 552 | 0.630 | Why? |  | Staphylococcus aureus | 1 | 2023 | 451 | 0.620 | Why? |  | Child, Preschool | 13 | 2024 | 11013 | 0.570 | Why? |  | Glucocorticoids | 2 | 2020 | 596 | 0.570 | Why? |  | Patient Discharge Summaries | 1 | 2017 | 10 | 0.540 | Why? |  | Physicians, Primary Care | 1 | 2020 | 235 | 0.530 | Why? |  | Biomedical Research | 1 | 2023 | 688 | 0.520 | Why? |  | Positive-Pressure Respiration | 1 | 2017 | 80 | 0.520 | Why? |  | Pulmonary Embolism | 1 | 2019 | 222 | 0.510 | Why? |  | Dexamethasone | 3 | 2024 | 374 | 0.460 | Why? |  | Emergency Medical Services | 2 | 2021 | 545 | 0.460 | Why? |  | Health Literacy | 1 | 2017 | 168 | 0.450 | Why? |  | Prednisone | 3 | 2020 | 239 | 0.440 | Why? |  | Physicians | 1 | 2022 | 902 | 0.430 | Why? |  | Prospective Studies | 10 | 2024 | 7543 | 0.390 | Why? |  | Acute Disease | 4 | 2024 | 1000 | 0.370 | Why? |  | Humans | 28 | 2024 | 136899 | 0.360 | Why? |  | Bronchodilator Agents | 3 | 2024 | 248 | 0.360 | Why? |  | Patient Readmission | 1 | 2017 | 693 | 0.360 | Why? |  | Prednisolone | 2 | 2020 | 83 | 0.330 | Why? |  | Caregivers | 1 | 2017 | 865 | 0.310 | Why? |  | Male | 14 | 2024 | 67308 | 0.260 | Why? |  | Patient Discharge | 3 | 2024 | 887 | 0.250 | Why? |  | Disease Progression | 2 | 2024 | 2744 | 0.230 | Why? |  | Hospitalization | 4 | 2022 | 2183 | 0.230 | Why? |  | Infant | 7 | 2024 | 9408 | 0.230 | Why? |  | Rhinovirus | 1 | 2024 | 57 | 0.220 | Why? |  | Picornaviridae Infections | 1 | 2024 | 46 | 0.220 | Why? |  | Risk Factors | 4 | 2024 | 10313 | 0.220 | Why? |  | Quality of Life | 4 | 2024 | 2847 | 0.210 | Why? |  | Enterotoxins | 1 | 2023 | 87 | 0.210 | Why? |  | Female | 12 | 2024 | 72703 | 0.200 | Why? |  | Bronchiolitis | 1 | 2024 | 91 | 0.200 | Why? |  | Respiratory Syncytial Virus, Human | 1 | 2023 | 75 | 0.190 | Why? |  | Viruses | 1 | 2023 | 111 | 0.190 | Why? |  | Respiratory Syncytial Virus Infections | 1 | 2023 | 127 | 0.190 | Why? |  | Magnesium | 1 | 2022 | 157 | 0.180 | Why? |  | Educational Status | 1 | 2024 | 482 | 0.180 | Why? |  | Administration, Intravenous | 1 | 2022 | 152 | 0.180 | Why? |  | Delphi Technique | 1 | 2023 | 267 | 0.180 | Why? |  | Dyspnea | 1 | 2023 | 251 | 0.170 | Why? |  | Schools | 1 | 2024 | 463 | 0.170 | Why? |  | Allergens | 1 | 2023 | 405 | 0.170 | Why? |  | Surveys and Questionnaires | 2 | 2023 | 5730 | 0.160 | Why? |  | Consensus | 1 | 2023 | 678 | 0.160 | Why? |  | Thrombectomy | 1 | 2019 | 64 | 0.150 | Why? |  | Administration, Oral | 1 | 2020 | 811 | 0.140 | Why? |  | Vena Cava Filters | 1 | 2019 | 61 | 0.140 | Why? |  | Self Report | 1 | 2022 | 827 | 0.140 | Why? |  | Adolescent | 5 | 2024 | 21402 | 0.140 | Why? |  | Infant, Newborn | 3 | 2024 | 6043 | 0.140 | Why? |  | Ipratropium | 1 | 2017 | 6 | 0.140 | Why? |  | Influenza, Human | 1 | 2023 | 626 | 0.130 | Why? |  | Nebulizers and Vaporizers | 1 | 2017 | 86 | 0.130 | Why? |  | Albuterol | 1 | 2017 | 107 | 0.130 | Why? |  | Feasibility Studies | 1 | 2020 | 943 | 0.130 | Why? |  | Single-Blind Method | 1 | 2017 | 288 | 0.130 | Why? |  | Sepsis | 1 | 2022 | 610 | 0.130 | Why? |  | Retrospective Studies | 3 | 2024 | 15514 | 0.120 | Why? |  | Tertiary Care Centers | 1 | 2017 | 160 | 0.120 | Why? |  | Phenotype | 1 | 2023 | 3201 | 0.120 | Why? |  | Health Surveys | 1 | 2017 | 520 | 0.110 | Why? |  | Prognosis | 1 | 2023 | 4011 | 0.110 | Why? |  | Anticoagulants | 1 | 2019 | 662 | 0.110 | Why? |  | Combined Modality Therapy | 1 | 2017 | 1240 | 0.110 | Why? |  | Treatment Outcome | 2 | 2024 | 10768 | 0.100 | Why? |  | Ambulatory Care | 1 | 2017 | 528 | 0.100 | Why? |  | Patient Satisfaction | 1 | 2017 | 657 | 0.100 | Why? |  | Biomarkers | 1 | 2023 | 4148 | 0.090 | Why? |  | Primary Health Care | 1 | 2020 | 1741 | 0.080 | Why? |  | United States | 2 | 2024 | 14595 | 0.080 | Why? |  | Pediatrics | 1 | 2017 | 1119 | 0.070 | Why? |  | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1324 | 0.070 | Why? |  | Adult | 2 | 2020 | 37595 | 0.060 | Why? |  | Uncertainty | 1 | 2024 | 125 | 0.050 | Why? |  | Patient Acuity | 1 | 2022 | 45 | 0.050 | Why? |  | Treatment Failure | 1 | 2024 | 353 | 0.050 | Why? |  | Anti-Bacterial Agents | 2 | 2022 | 1790 | 0.050 | Why? |  | Fever | 1 | 2022 | 307 | 0.040 | Why? |  | Aftercare | 1 | 2022 | 210 | 0.040 | Why? |  | ROC Curve | 1 | 2022 | 543 | 0.040 | Why? |  | Epinephrine | 1 | 2021 | 145 | 0.040 | Why? |  | Young Adult | 1 | 2017 | 13157 | 0.040 | Why? |  | Fatigue | 1 | 2022 | 329 | 0.040 | Why? |  | Pneumonia, Viral | 1 | 2024 | 368 | 0.040 | Why? |  | Odds Ratio | 1 | 2022 | 1063 | 0.040 | Why? |  | Hospitals, Pediatric | 1 | 2022 | 533 | 0.040 | Why? |  | Middle Aged | 1 | 2020 | 33118 | 0.040 | Why? |  | Tomography, X-Ray Computed | 1 | 2024 | 2670 | 0.030 | Why? |  | Follow-Up Studies | 1 | 2022 | 5126 | 0.020 | Why? |  | Cohort Studies | 1 | 2022 | 5711 | 0.020 | Why? |  | Cross-Sectional Studies | 1 | 2022 | 5398 | 0.020 | Why? |  | Lung | 1 | 2024 | 4046 | 0.020 | Why? | 
 | 
																	
																		
																			
																					
    Navanandan's Networks
 
Click the "See All" links for more information and interactive visualizations!
 Concepts  Derived automatically from this person's publications._ Co-Authors  People in Profiles who have published with this person._ Similar People  People who share similar concepts with this person._ 
            
                Same Department   
				People who are also in this person's primary department.
			 Physical Neighbors  People whose addresses are nearby this person._ |